Regeneron Pharmaceuticals, Inc.REGNNASDAQ
Loading
A large-scale business, with exceptional profitability valued in line with the market.
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.
Comprehensive financial statement data for deep analysis
| Metric | Dec 21 | Dec 22 | Dec 23 | Dec 24 | Dec 25 |
|---|---|---|---|---|---|
| Return on Equity | - | - | - | - | - |
| Return on Invested Capital | - | - | - | - | - |
| Gross Margin | 83.1% | 86.0%↑3.5% | 82.9%↓3.6% | 86.1%↑3.9% | 85.4%↓0.9% |
| Operating Margin | 55.7% | 44.2%↓20.5% | 33.2%↓25.1% | 28.1%↓15.2% | 24.9%↓11.2% |
| Net Margin | 50.2% | 35.6%↓29.1% | 30.1%↓15.4% | 31.1%↑3.1% | 31.4%↑1.1% |
| Earnings Yield | - | - | - | - | - |